deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02942576

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (ELIMINATE-AF)

A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Conditions Atrial Fibrillation
Interventions Edoxaban VKA-Based Regimen
Updated 16 times since 2017 Last updated: Aug 26, 2019 Started: Mar 21, 2017 Primary completion: Sep 24, 2018 Completion: Sep 24, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02942576, this PHASE3 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, it has been updated 16 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Mar 2024 · 38 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Mar 2024 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Apr 2019 — Oct 2019 [monthly]

    Completed PHASE3

  3. Jan 2019 — Apr 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  8. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE3

  10. Feb 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Antwerp, Belgium , Arezzo, Italy , Bad Krozingen, Germany , Barcelona, Spain , Berlin, Germany , Bielefeld, Germany , Blackpool, United Kingdom , Bournemouth, United Kingdom , Brno, Czechia and 53 more locations